Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALM1 | P0DP23 | 1/20 | 0.44 |
| ▸ | BCL2 | P10415 | 1/20 | 0.38 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | CTRC | Q99895 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL218277 | 0.82 | MAOA (0.39) | HTR2ARAB9AALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL7900000 | 0.80 | NPC1 (0.36) | RAB9AALDH1A1SMN1; SMN2TDP1NPC1 | |
| SCHEMBL3745997 | 0.77 | ALDH1A1 (0.33) | RAB9AALDH1A1SMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL6684516 | 0.77 | NPC1 (0.43) | CALM1RAB9AALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL7703948 | 0.77 | MEN1 (0.45) | TDP1MEN1KMT2A | |
| SCHEMBL5519430 | 0.75 | TAAR1 (0.43) | RAB9ANPC1TAAR1 | |
| SCHEMBL3741895 | 0.74 | EPHX1 (0.57) | CYP2D6TAAR1LTA4H | |
| SCHEMBL406701 | 0.74 | CES1 (0.42) | RAB9AALDH1A1SMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL1155203 | 0.74 | TRPA1 (0.38) | CYP1A2TSHRADRA1DADRA1AADRA1B | |
| SCHEMBL7723121 | 0.72 | CALM1 (0.58) | CALM1BCL2BCL2L1HTR2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 208 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109060979-A | A kind of measuring method of (methylenedioxy) benzyl ethylene toxin | 成都中医药大学 | 2018-12-21 | — | — | CN | claimed |
| EP-2986286-A1 | GALLOYL BENZAMIDE-BASED COMPOUNDS AS JNK MODULATORS | Universita' Degli Studi di Bari (IT) | 2016-02-24 | — | — | EP | claimed |
| WO-2014170706-A1 | GALLOYL BENZAMIDE-BASED COMPOUNDS AS JNK MODULATORS | UNIVERSITÀ DEGLI STUDI DI BARI (IT) | 2014-10-23 | — | — | WO | claimed |
| EP-1954678-B1 | NOVEL NK1 AND NK2 ANTAGONISTS | ABBOTT PRODUCTS GMBH (DE) | 2012-03-21 | — | — | EP | claimed |
| US-7592344-B2 | NK1 and NK2-antagonists and compositions and methods of using the same | SOLVAY PHARMACEUTICALS GMBH (DE) | 2009-09-22 | — | — | US | claimed |
| EP-1954678-A1 | NOVEL NK1 AND NK2 ANTAGONISTS | Solvay Pharmaceuticals GmbH (DE) | 2008-08-13 | — | — | EP | claimed |
| US-7365085-B2 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-29 | — | — | US | claimed |
| US-20070149537-A1 | NK1 and NK2-antagonists and compositions and methods of using the same | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-06-28 | — | — | US | claimed |
| WO-2007063086-A1 | NOVEL NK1 AND NK2 ANTAGONISTS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-06-07 | — | — | WO | claimed |
| EP-1680419-A1 | IMPROVED AZA-BRIDGED-BICYCLIC AMINO ACID DERIVATIVES AS A4 INTEGRIN ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-19 | — | — | EP | claimed |
| EP-1575495-A2 | COMPOUNDS AND METHODS | SmithKline Beecham Corporation (US) | 2005-09-21 | — | — | EP | claimed |
| US-20050176755-A1 | Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-08-11 | — | — | US | claimed |
| US-20050113580-A1 | Amide compounds and methods of using the same | SMITHKLINE BEECHAM CORP | 2005-05-26 | — | — | US | claimed |
| WO-2005042529-A1 | IMPROVED AZA-BRIDGED-BICYCLIC AMINO ACID DERIVATIVES AS A4 INTEGRIN ANTAGONISTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-05-12 | — | — | WO | claimed |
| US-20040110809-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-06-10 | — | — | US | claimed |
| EP-1370538-A1 | METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | claimed |
| EP-0728758-B1 | Dioxopyrrolo-pyrrole derivatives | HOFFMANN LA ROCHE (CH) | 2003-10-15 | — | — | EP | claimed |
| WO-2003082205-A2 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-09 | — | — | WO | claimed |
| WO-2002074752-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | claimed |
| CN-105853246-B | Keratin dyeing compositions and application thereof comprising free radical scavenger and chelating agent | 诺赛尔股份有限公司 | 2019-07-26 | — | — | CN | disclosed |
| CN-109060979-A | A kind of measuring method of (methylenedioxy) benzyl ethylene toxin | 成都中医药大学 | 2018-12-21 | — | — | CN | disclosed |
| CN-109060979-A | A kind of measuring method of (methylenedioxy) benzyl ethylene toxin | 成都中医药大学 | 2018-12-21 | — | — | CN | disclosed |
| CN-109060979-A | A kind of measuring method of (methylenedioxy) benzyl ethylene toxin | 成都中医药大学 | 2018-12-21 | — | — | CN | disclosed |
| EP-2986286-A1 | GALLOYL BENZAMIDE-BASED COMPOUNDS AS JNK MODULATORS | Universita' Degli Studi di Bari (IT) | 2016-02-24 | — | — | EP | disclosed |
| US-9175061-B2 | Protein conjugates and methods for their preparation | NOVO NORDISK HEALTH CARE AG (CH) | 2015-11-03 | — | — | US | disclosed |
| US-20150274674-A1 | PYRAZOLE OR TRIAZOLE COMPOUNDS AND THEIR USE FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING SOMATIC MUTATION-RELATED DISEASES | PTC THERAPEUTICS, INC. (US) | 2015-10-01 | — | — | US | disclosed |
| US-RE45670-E1 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2015-09-15 | — | — | US | disclosed |
| US-9051342-B2 | Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation related diseases | PTC THERAPEUTICS, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-20150126477-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2015-05-07 | — | — | US | disclosed |
| WO-2014170706-A1 | GALLOYL BENZAMIDE-BASED COMPOUNDS AS JNK MODULATORS | UNIVERSITÀ DEGLI STUDI DI BARI (IT) | 2014-10-23 | — | — | WO | disclosed |
| US-RE45183-E1 | Heteroaryl-ureas and their use as glucokinase activators | NOVO NORDISK A/S (DK) | 2014-10-07 | — | — | US | disclosed |
| EP-1531815-B1 | GLUCOKINASE ACTIVATORS | NOVO NORDISK AS (DK) | 2014-09-24 | — | — | EP | disclosed |
| US-20140045836-A1 | [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE DERIVATIVES AS HSP90 MODULATORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-02-13 | — | — | US | disclosed |
| US-8586614-B2 | Urea glucokinase activators | NOVO NORDISK A/S (DK) | 2013-11-19 | — | — | US | disclosed |
| US-8580783-B2 | [1,2,4]triazolo [1,5-c]pyrimidine derivatives as Hsp90 modulators | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-11-12 | — | — | US | disclosed |
| US-8486892-B2 | Blood coagulation factor inhibitors | NOVO NORDISK HEALTH CARE AG (CH) | 2013-07-16 | — | — | US | disclosed |
| EP-1904467-B1 | Urea glucokinase activators | NOVO NORDISK AS (DK) | 2013-05-01 | — | — | EP | disclosed |
| US-8399488-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| EP-1723128-B1 | HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS | NOVO NORDISK AS (DK) | 2012-11-07 | — | — | EP | disclosed |
| EP-2503985-A1 | POWDERED HAIR COLORING AND BLEACHING COMPOSITIONS | The Procter & Gamble Company (US) | 2012-10-03 | — | — | EP | disclosed |
| US-8263634-B2 | Heteroaryl-ureas and their use as glucokinase activators | NOVO NORDISK A/S (DK) | 2012-09-11 | — | — | US | disclosed |
| US-20120184546-A1 | [1,2,4]TRIAZOLO [1,5-C]PYRIMIDINE DERIVATIVES AS HSP90 MODULATORS | NERVIANO MEDICAL SCIENCES S.R.L (IT) | 2012-07-19 | — | — | US | disclosed |
| EP-2475665-A1 | [1,2,4]TRIAZOLO [1,5-c]PYRIMIDINE DERIVATIVES AS Hsup90 MODULATORS | Nerviano Medical Sciences S.r.l. (IT) | 2012-07-18 | — | — | EP | disclosed |
| EP-2471533-A1 | Aryl carbonyl derivatives as therapeutic agents | Novo Nordisk A/S (DK) | 2012-07-04 | — | — | EP | disclosed |
| US-20120122850-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| EP-2444397-A1 | Heteroaryl-ureas and their use as glucokinase activators | Novo Nordisk A/S (DK) | 2012-04-25 | — | — | EP | disclosed |
| US-8148413-B2 | N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes | TRANSTECH PHARMA, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148412-B2 | e.g. {-[3-Cyclopentyl-2-(4-methane sulfonyl-phenyl)-propionylamino]-5-methyl-thiazol-4-yl}-acetic acid ethyl ester; antidiabetic and hypoglycemic agent; non-insulin dependent diabetis, obesity, impaired glucose tolerance, eating disorder, dyslipidemia, hyperlipidemia, hypertension | NOVO NORDISK A/S (DK) | 2012-04-03 | — | — | US | disclosed |
| EP-1954678-B1 | NOVEL NK1 AND NK2 ANTAGONISTS | ABBOTT PRODUCTS GMBH (DE) | 2012-03-21 | — | — | EP | disclosed |
| EP-1904438-B1 | DICYCLOALKYLCARBAMOYL UREAS AS GLUCOKINASE ACTIVATORS | NOVO NORDISK AS (DK) | 2012-02-29 | — | — | EP | disclosed |
| US-8119796-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| EP-2402323-A2 | Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases | PTC Therapeutics, Inc. (US) | 2012-01-04 | — | — | EP | disclosed |
| US-20110301158-A1 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | NOVO NORDISK A/S (DK) | 2011-12-08 | — | — | US | disclosed |
| US-8063081-B2 | N-(2-Phenoxyphenyl)-N'-(thiazol-2-yl)urea; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase | NOVO NORDISK A/S (DK) | 2011-11-22 | — | — | US | disclosed |
| US-20110281851-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2011-11-17 | — | — | US | disclosed |
| EP-2377856-A1 | Urea glucokinase activators | NOVO NORDISK A/S (DK) | 2011-10-19 | — | — | EP | disclosed |
| US-20110229453-A1 | BLOOD COAGULATION FACTOR INHIBITORS | NOVO NORDISK HEALTH CARE AG (CH) | 2011-09-22 | — | — | US | disclosed |
| US-8022066-B2 | 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-09-20 | — | — | US | disclosed |
| EP-2097388-B1 | NOVEL 2-(2-HYDROXYPHENYL)BENZIMIDAZOLES USEFUL FOR TREATING OBESITY AND DIABETES | HIGH POINT PHARMACEUTICALS LLC (US) | 2011-09-07 | — | — | EP | disclosed |
| EP-2363129-A1 | Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases | PTC Therapeutics, Inc. (US) | 2011-09-07 | — | — | EP | disclosed |
| US-8013152-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-7999114-B2 | Dicycloalkylcarbamoyl ureas as glucokinase activators | NOVO NORDISK A/S (DK) | 2011-08-16 | — | — | US | disclosed |
| WO-2011085140-A1 | THICKENED HAIR COLOURANT AND BLEACHING COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2011-07-14 | — | — | WO | disclosed |
| US-20110144017-A1 | Protein conjugates and methods for their preparation | NOVO NORDISK HEALTH CARE AG (CH) | 2011-06-16 | — | — | US | disclosed |
| WO-2011065934-A1 | POWDERED HAIR COLORING AND BLEACHING COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2011-06-03 | — | — | WO | disclosed |
| US-20110130402-A1 | HETEROAROMATIC GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2011-06-02 | — | — | US | disclosed |
| US-7939690-B2 | Haloalkylsulfone substituted compounds useful for treating obesity and diabetes | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-05-10 | — | — | US | disclosed |
| EP-2316452-A1 | Pyrrol derivatives, uses thereof | PTC Therapeutics, Inc. (US) | 2011-05-04 | — | — | EP | disclosed |
| US-20110082144-A1 | N-HETEROARYL INDOLE CARBOXAMIDES AND ANALOGUES THEREOF, FOR USE AS GLUCOKINASE ACTIVATORS IN THE TREATMENT OF DIABETES | TRANSTECH PHARMA, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| EP-2305648-A1 | Amide derivatives useful as glucokinase activators | Novo Nordisk A/S (DK) | 2011-04-06 | — | — | EP | disclosed |
| US-20110077234-A1 | Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2011-03-31 | — | — | US | disclosed |
| US-7915299-B2 | 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-03-29 | — | — | US | disclosed |
| WO-2011029775-A1 | [1,2,4]TRIAZOLO [1,5-c]PYRIMIDINE DERIVATIVES AS Hsup90 MODULATORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-03-17 | — | — | WO | disclosed |
| US-20110060019-A1 | HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2011-03-10 | — | — | US | disclosed |
| US-7897628-B2 | {2-[3-(4-Methyl-2-[2-methypropoxy]phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase | NOVO NORDISK A/S (DK) | 2011-03-01 | — | — | US | disclosed |
| US-7884210-B2 | {2-[3-(2-Cyclohex-1-enyl-ethyl)-3-(trans-4-methyl-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid; for treatment of type 2 diabetes | NOVO NORDISK A/S (DK) | 2011-02-08 | — | — | US | disclosed |
| US-7872139-B2 | e.g.1,1-Dicyclohexyl-3-[5-(pyridin-2-ylsulfanyl)-thiazol-2-yl]-urea; useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial, in particular, type 2 diabetes | NOVO NORDISK A/S (DK) | 2011-01-18 | — | — | US | disclosed |
| US-20110003752-A1 | New Blood Coagulation Factor Inhibitors | NOVO NORDISK HEALTH CARE A/G (CH) | 2011-01-06 | — | — | US | disclosed |
| US-7851636-B2 | {2-[3-Cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid; useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial; antidiabetic agents | NOVO NORDISK A/S (DK) | 2010-12-14 | — | — | US | disclosed |
| US-7812043-B2 | N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes | TRANSTECH PHARMA, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| EP-2235042-A1 | NEW BLOOD COAGULATION FACTOR INHIBITORS | Novo Nordisk Health Care AG (CH) | 2010-10-06 | — | — | EP | disclosed |
| US-20100249161-A1 | 2- ( 2 -HYDROXYPHENYL) -QUINAZOLIN-4-ONES USEFUL FOR TREATING OBESITY AND DIABETES | HIGH POINT PHARMACEUTICALS, LLC | 2010-09-30 | — | — | US | disclosed |
| US-20100204288-A1 | {2-[3-Cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid; useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial; antidiabetic agents | NOVO NORDISK A/S (DK) | 2010-08-12 | — | — | US | disclosed |
| US-20100197667-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| US-7741479-B2 | Urea inhibitors of MAP kinases | LOCUS PHARMACEUTICALS, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| EP-2190860-A1 | BLOOD COAGULATION FACTOR INHIBITORS | Novo Nordisk Health Care AG (CH) | 2010-06-02 | — | — | EP | disclosed |
| US-7728144-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC (US) | 2010-06-01 | — | — | US | disclosed |
| EP-1575575-B1 | SAFE CHEMICAL UNCOUPLERS FOR THE TREATMENT OF OBESITY | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-05-19 | — | — | EP | disclosed |
| US-20100113536-A1 | HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | HIGH POINT PHARMACEUTICALS, LLC | 2010-05-06 | — | — | US | disclosed |
| US-20100075932-A1 | NOVEL SALICYLIC ANILIDES | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100063122-A1 | NOVEL 2-(2-HYDROXYPHENYL)BENZIMlDAZOLES USEFUL FOR TREATING OBESITY AND DIABETES | HIGH POINT PHARMACEUTICALS, LLC | 2010-03-11 | — | — | US | disclosed |
| US-20100041657-A1 | HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDICK A/S (DK) | 2010-02-18 | — | — | US | disclosed |
| US-7645791-B2 | Salicylic anilides | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-01-12 | — | — | US | disclosed |
| US-20090325941-A1 | NOVEL 2-(2-HYDROXYPHENYL) BENZOTHIADIAZINES USEFUL FOR TREATING OBESITY AND DIABETES | HIGH POINT PHARMACEUTICALS, LLC | 2009-12-31 | — | — | US | disclosed |
| US-7598391-B2 | Heteroaryl-ureas and their use as glucokinase activators | NOVO NORDISK A/S (DK) | 2009-10-06 | — | — | US | disclosed |
| US-7592344-B2 | NK1 and NK2-antagonists and compositions and methods of using the same | SOLVAY PHARMACEUTICALS GMBH (DE) | 2009-09-22 | — | — | US | disclosed |
| EP-2097391-A1 | 2- ( 2 -HYDROXYPHENYL) -QUINAZOLIN-4-ONES USEFUL FOR TREATING OBESITY AND DIABETES | High Point Pharmaceuticals, LLC (US) | 2009-09-09 | — | — | EP | disclosed |
| EP-2097380-A1 | NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | High Point Pharmaceuticals, LLC (US) | 2009-09-09 | — | — | EP | disclosed |
| EP-2097388-A1 | NOVEL 2-(2-HYDROXYPHENYL)BENZIMIDAZOLES USEFUL FOR TREATING OBESITY AND DIABETES | High Point Pharmaceuticals, LLC (US) | 2009-09-09 | — | — | EP | disclosed |
| US-7582769-B2 | Dicycloalkyl urea glucokinase activators | NOVO NORDISK A/S (DK) | 2009-09-01 | — | — | US | disclosed |
| US-20090216013-A1 | e.g.1,1-Dicyclohexyl-3-[5-(pyridin-2-ylsulfanyl)-thiazol-2-yl]-urea; useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial, in particular, type 2 diabetes | NOVO NORDISK A/S (DK) | 2009-08-27 | — | — | US | disclosed |
| EP-2086951-A1 | NOVEL 2-(2-HYDROXYPHENYL) BENZOTHIADIAZINES USEFUL FOR TREATING OBESITY AND DIABETES | High Point Pharmaceuticals, LLC (US) | 2009-08-12 | — | — | EP | disclosed |
| WO-2009092758-A1 | NEW BLOOD COAGULATION FACTOR INHIBITORS | NOVO NORDISK HEALTH CARE AG (DK) | 2009-07-30 | — | — | WO | disclosed |
| EP-1625112-B1 | NOVEL COMPOUNDS FOR TREATMENT OF OBESITY | HIGH POINT PHARMACEUTICALS LLC (US) | 2009-07-22 | — | — | EP | disclosed |
| US-7541373-B2 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2009-06-02 | — | — | US | disclosed |
| US-20090118501-A1 | Dicycloalkyl Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2009-05-07 | — | — | US | disclosed |
| US-20090105482-A1 | Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2009-04-23 | — | — | US | disclosed |
| EP-2040757-A2 | NEW PROTEIN CONJUGATES AND METHODS FOR THEIR PREPARATION | Novo Nordisk Health Care AG (CH) | 2009-04-01 | — | — | EP | disclosed |
| US-20090062396-A1 | Novel Haloalkoxy-Substituted Salicylic Anilides | NOVO NORDISK A/S (DK) | 2009-03-05 | — | — | US | disclosed |
| WO-2009024571-A1 | BLOOD COAGULATION FACTOR INHIBITORS | NOVO NORDISK HEALTH CARE AG (DK) | 2009-02-26 | — | — | WO | disclosed |
| US-20090018161-A1 | METHOD FOR PROMOTING GASTROINTESTINAL FUNCTION AND METHOD FOR SCREENING FOR PROMOTER OF GASTROINTESTINAL FUNCTION | AJINOMOTO CO. INC. (JP) | 2009-01-15 | — | — | US | disclosed |
| US-20090005434-A1 | Novel Salicylic Anilides | NOVO NORDISK A/S (DK) | 2009-01-01 | — | — | US | disclosed |
| US-20080319028-A1 | Dicycloalkylcarbamoyl Ureas As Glucokinase Activators | NOVO NORDISK A/S (DK) | 2008-12-25 | — | — | US | disclosed |
| US-20080280869-A1 | Pyrazole or Triazole Compounds and Their Use for the Manufacture of a Medicament for Treating Somatic Mutation-Related Diseases | PTC THERAPEUTICS, INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080255240-A1 | Sulfonamide Derivatives | NOVO NORDISK A/S (DK) | 2008-10-16 | — | — | US | disclosed |
| US-20080234381-A1 | Novel Trifluoromethoxy-Substituted Aryl Anilides | NOVO NORDISK A/S (DK) | 2008-09-25 | — | — | US | disclosed |
| WO-2008107362-A2 | STABILISER AND INHIBITORS OF FACTOR VII | NOVO NORDISK HEALTH CARE AG (DK) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008107363-A1 | NEW BLOOD COAGULATION FACTOR INHIBITORS | NOVO NORDISK HEALTH CARE AG (DK) | 2008-09-12 | — | — | WO | disclosed |
| EP-1967522-A1 | New blood coagulation factor inhibitors | NOVO NORDISK A/S (DK) | 2008-09-10 | — | — | EP | disclosed |
| EP-1954678-A1 | NOVEL NK1 AND NK2 ANTAGONISTS | Solvay Pharmaceuticals GmbH (DE) | 2008-08-13 | — | — | EP | disclosed |
| US-20080139562-A1 | Heteroaromatic Glucokinase Activators | NOVO NORDISK A/S (DK) | 2008-06-12 | — | — | US | disclosed |
| US-7384967-B2 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2008-06-10 | — | — | US | disclosed |
| WO-2008059023-A1 | NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | HIGH POINT PHARMACEUTICALS, LLC (US) | 2008-05-22 | — | — | WO | disclosed |
| US-20080119454-A1 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2008-05-22 | — | — | US | disclosed |
| US-20080119455-A1 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2008-05-22 | — | — | US | disclosed |
| WO-2008059025-A1 | NOVEL 2-(2-HYDROXYPHENYL) BENZOTHIADIAZINES USEFUL FOR TREATING OBESITY AND DIABETES | HIGH POINT PHARMACEUTICALS, LLC (US) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008059026-A1 | NOVEL 2-(2-HYDROXYPHENYL)BENZIMIDAZOLES USEFUL FOR TREATING OBESITY AND DIABETES | HIGH POINT PHARMACEUTICALS, LLC (US) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008059024-A1 | 2- ( 2 -HYDROXYPHENYL) -QUINAZOLIN-4-ONES USEFUL FOR TREATING OBESITY AND DIABETES | HIGH POINT PHARMACEUTICALS, LLC (US) | 2008-05-22 | — | — | WO | disclosed |
| US-20080113944-A1 | Novel Indole Derivatives | NOVO NORDISK A/S (DK) | 2008-05-15 | — | — | US | disclosed |
| US-7365085-B2 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-29 | — | — | US | disclosed |
| EP-1904466-A1 | DICYCLOALKYL UREA GLUCOKINASE ACTIVATORS | Novo Nordisk A/S (DK) | 2008-04-02 | — | — | EP | disclosed |
| EP-1904438-A1 | DICYCLOALKYLCARBAMOYL UREAS AS GLUCOKINASE ACTIVATORS | Novo Nordisk A/S (DK) | 2008-04-02 | — | — | EP | disclosed |
| EP-1904467-A1 | UREA GLUCOKINASE ACTIVATORS | Novo Nordisk A/S (DK) | 2008-04-02 | — | — | EP | disclosed |
| EP-1893577-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2008-03-05 | — | — | EP | disclosed |
| EP-1888513-A1 | NOVEL TRIFLUOROMETHOXY-SUBSTITUTED ARYL ANILIDES | NOVO NORDISK A/S (DK) | 2008-02-20 | — | — | EP | disclosed |
| EP-1888508-A2 | NOVEL HALOALKOXY-SUBSTITUTED SALICYLIC ANILIDES | NOVO NORDISK A/S (DK) | 2008-02-20 | — | — | EP | disclosed |
| EP-1881961-A1 | NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDISK A/S (DK) | 2008-01-30 | — | — | EP | disclosed |
| WO-2008003750-A2 | NEW PROTEIN CONJUGATES AND METHODS FOR THEIR PREPARATION | NOVO NORDISK HEALTH CARE AG (DK) | 2008-01-10 | — | — | WO | disclosed |
| EP-1828169-A2 | UREA INHIBITORS OF MAP KINASES | Locus Pharmaceuticals, Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| EP-1824835-A1 | HETEROAROMATIC GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2007-08-29 | — | — | EP | disclosed |
| US-20070149537-A1 | NK1 and NK2-antagonists and compositions and methods of using the same | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-06-28 | — | — | US | disclosed |
| EP-1799207-A2 | PYRAZOLE OR TRIAZOLE COMPOUNDS AND THEIR USE FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING SOMATIC MUTATION-RELATED DISEASES | PTC Therapeutics, Inc. (US) | 2007-06-27 | — | — | EP | disclosed |
| WO-2007063086-A1 | NOVEL NK1 AND NK2 ANTAGONISTS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-06-07 | — | — | WO | disclosed |
| US-20070054897-A1 | 1,1-Dicyclohexyl-3-thiazol-2-yl-urea, 3-(5-Chloro-thiazol-2-yl)-1,1-dicyclohexyl-urea, for example; useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial, in particular, type 2 diabetes | NOVO NORDISK A/S (DK) | 2007-03-08 | — | — | US | disclosed |
| EP-1758856-A2 | INDOLE DERIVATIVES FOR THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2007-03-07 | — | — | EP | disclosed |
| EP-1756025-A1 | SULFONAMIDE DERIVATIVES | NOVO NORDISK A/S (DK) | 2007-02-28 | — | — | EP | disclosed |
| US-20070027140-A1 | N-heteroaryl indole carboxamides and analogues thereof, for use as glcokinase activators in the treatment of diabetes | NOVO NORDISK A/S (DK) | 2007-02-01 | — | — | US | disclosed |
| WO-2007006760-A1 | DICYCLOALKYL UREA GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007006761-A1 | DICYCLOALKYLCARBAMOYL UREAS AS GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007006814-A1 | UREA GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2007-01-18 | — | — | WO | disclosed |
| US-20070010559-A1 | Indole derivatives for use as chemical uncoupler | NOVO NORDISK A/S (DK) | 2007-01-11 | — | — | US | disclosed |
| US-20070004799-A1 | Novel compounds for the treatment of obesity | NOVO NORDISK A/S (DK) | 2007-01-04 | — | — | US | disclosed |
| US-20070004794-A1 | Novel salicylic anilides | NOVO NORDISK A/S (DK) | 2007-01-04 | — | — | US | disclosed |
| WO-2006138218-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2006-12-28 | — | — | WO | disclosed |
| US-20060281740-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2006-12-14 | — | — | US | disclosed |
| US-7148242-B2 | N-formyl hydroxylamine compounds, compositions and methods of use | NOVARTIS AG (CH) | 2006-12-12 | — | — | US | disclosed |
| WO-2006125778-A1 | NOVEL TRIFLUOROMETHOXY-SUBSTITUTED ARYL ANILIDES | NOVO NORDISK A/S (DK) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006125781-A2 | HALOALKOXY-SUBSTITUTED SALICYLIC ANILIDES | NOVO NORDISK A/S (DK) | 2006-11-30 | — | — | WO | disclosed |
| EP-1723128-A1 | HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2006-11-22 | — | — | EP | disclosed |
| WO-2006120178-A1 | NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDISK A/S (DK) | 2006-11-16 | — | — | WO | disclosed |
| US-20060183783-A1 | Aryl carbonyl derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2006-08-17 | — | — | US | disclosed |
| EP-1689700-A1 | NOVEL SALICYLIC ANILIDES | NOVO NORDISK A/S (DK) | 2006-08-16 | — | — | EP | disclosed |
| EP-1689392-A1 | N-HETEROARYL INDOLE CARBOXAMIDES AND ANALOGUES THEREOF, FOR USE AS GLUCOKINASE ACTIVATORS IN THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2006-08-16 | — | — | EP | disclosed |
| EP-1689707-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2006-08-16 | — | — | EP | disclosed |
| EP-1689710-A1 | INDOLE DERIVATIVES FOR USE AS CHEMICAL UNCOUPLER | NOVO NORDISK A/S (DK) | 2006-08-16 | — | — | EP | disclosed |
| US-20060167247-A1 | Urea inhibitors of MAP kinases | LOCUS PHARMACEUTICALS, INC. | 2006-07-27 | — | — | US | disclosed |
| EP-1680419-A1 | IMPROVED AZA-BRIDGED-BICYCLIC AMINO ACID DERIVATIVES AS A4 INTEGRIN ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-19 | — | — | EP | disclosed |
| WO-2006062982-A2 | UREA INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
| US-20060128662-A1 | Novel compounds for treatment of obesity | NOVO NORDISK A/S (DK) | 2006-06-15 | — | — | US | disclosed |
| WO-2006058923-A1 | HETEROAROMATIC GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2006-06-08 | — | — | WO | disclosed |
| WO-2006044502-A2 | PYRAZOLE OR TRIAZOLE COMPOUNDS AND THEIR USE FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING SOMATIC MUTATION-RELATED DISEASES | PTC THERAPEUTICS, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| EP-1401828-B1 | N-FORMYL HYDROXYLAMINE COMPOUNDS AS INHIBITORS OF PDF | VICURON PHARM INC (US) | 2006-04-12 | — | — | EP | disclosed |
| EP-1625112-A1 | NOVEL COMPOUNDS FOR TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2006-02-15 | — | — | EP | disclosed |
| WO-2005105785-A2 | INDOLE DERIVATIVES FOR TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2005-11-10 | — | — | WO | disclosed |
| WO-2005105712-A1 | SULFONAMIDE DERIVATIVES | NOVO NORDISK A/S (DK) | 2005-11-10 | — | — | WO | disclosed |
| EP-1575495-A2 | COMPOUNDS AND METHODS | SmithKline Beecham Corporation (US) | 2005-09-21 | — | — | EP | disclosed |
| EP-1575575-A2 | SAFE CHEMICAL UNCOUPLERS FOR THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2005-09-21 | — | — | EP | disclosed |
| US-20050176755-A1 | Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-08-11 | — | — | US | disclosed |
| WO-2005066145-A1 | HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2005-07-21 | — | — | WO | disclosed |
| WO-2005051908-A1 | INDOLE DERIVATIVES FOR USE AS CHEMICAL UNCOUPLER | NOVO NORDISK A/S (DK) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005051894-A1 | NOVEL SALICYLIC ANILIDES | NOVO NORDISK A/S (DK) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005051900-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005049019-A1 | N-HETEROARYL INDOLE CARBOXAMIDES AND ANALOGUES THEREOF, FOR USE AS GLUCOKINASE ACTIVATORS IN THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2005-06-02 | — | — | WO | disclosed |
| US-20050113580-A1 | Amide compounds and methods of using the same | SMITHKLINE BEECHAM CORP | 2005-05-26 | — | — | US | disclosed |
| EP-1532980-A1 | N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes | NOVO NORDISK A/S (DK) | 2005-05-25 | — | — | EP | disclosed |
| EP-1531815-A1 | GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2005-05-25 | — | — | EP | disclosed |
| WO-2005042529-A1 | IMPROVED AZA-BRIDGED-BICYCLIC AMINO ACID DERIVATIVES AS A4 INTEGRIN ANTAGONISTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-05-12 | — | — | WO | disclosed |
| WO-2004101505-A1 | NOVEL COMPOUNDS FOR TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2004-11-25 | — | — | WO | disclosed |
| WO-2004099127-A1 | NOVEL COMPOUNDS AS KINASE INHIBITORS | NOVO NORDISK A/S (DK) | 2004-11-18 | — | — | WO | disclosed |
| EP-1458382-A1 | AMIDE DERIVATIVES AS GK ACTIVATORS | NOVO NORDISK A/S (DK) | 2004-09-22 | — | — | EP | disclosed |
| US-20040138301-A1 | Chemical uncouplers for the treatment of obesity | HIGH POINT PHARMACEUTICALS, LLC | 2004-07-15 | — | — | US | disclosed |
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2004-06-24 | — | — | US | disclosed |
| US-20040110809-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-06-10 | — | — | US | disclosed |
| WO-2004041256-A2 | SAFE CHEMICAL UNCOUPLERS FOR THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2004-05-21 | — | — | WO | disclosed |
| EP-1401828-A1 | N-FORMYL HYDROXYLAMINE COMPOUNDS AS INHIBITORS OF PDF | Vicuron Pharmaceuticals, Inc. (US) | 2004-03-31 | — | — | EP | disclosed |
| WO-2004002481-A1 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | NOVO NORDISK A/S (DK) | 2004-01-08 | — | — | WO | disclosed |
| EP-1370538-A1 | METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | disclosed |
| WO-2003082205-A2 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
| US-20030186944-A1 | Such as 4-(2-(3-dimethylaminobenzoylamino)phenoxy)phthalic acid for treatment/prevention of diabetes; for inhibiting liver glycogen phosphorylase; dietetics | KRISTIANSEN MARIT (DK) | 2003-10-02 | — | — | US | disclosed |
| US-20030171411-A1 | Amide derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2003-09-11 | — | — | US | disclosed |
| EP-1336607-A1 | Amide derivatives as glucokinase activators | NOVO NORDISK A/S (DK) | 2003-08-20 | — | — | EP | disclosed |
| WO-2003055482-A1 | AMIDE DERIVATIVES AS GK ACTIVATORS | NOVO NORDISK A/S (DK) | 2003-07-10 | — | — | WO | disclosed |
| US-6590118-B1 | Used in treatment of and/or prevention of diabetes, especially non-insulin dependent diabetes (Type 2 diabetes) | NOVO NORDISK A/S (DK) | 2003-07-08 | — | — | US | disclosed |
| US-20030045479-A1 | Novel N-formyl hydroxylamine compounds, compositions and methods of use | VICURON HOLDINGS LLC | 2003-03-06 | — | — | US | disclosed |
| WO-2002102790-A1 | N-FORMYL HYDROXYLAMINE COMPOUNDS AS INHIBITORS OF PDF | VICURON PHARMACEUTICALS INC. (US) | 2002-12-27 | — | — | WO | disclosed |
| WO-2002074752-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
| EP-1220832-A1 | NOVEL AROMATIC COMPOUNDS | NOVO NORDISK A/S (DK) | 2002-07-10 | — | — | EP | disclosed |
| WO-2001023347-A1 | NOVEL AROMATIC COMPOUNDS | NOVO NORDISK A/S (DK) | 2001-04-05 | — | — | WO | disclosed |
| WO-2001023347-A1 | NOVEL AROMATIC COMPOUNDS | NOVO NORDISK A/S (DK) | 2001-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139562-A1 | Heteroaromatic Glucokinase Activators | GCK, GCKR, PDXK | CALM1 3903/4885BCL2 1918/4885BCL2L1 2206/4885 |
| US-20040110809-A1 | Metalloproteinase inhibitors | MMP9, MMP2, MMP3 | CALM1 2687/4885BCL2 1140/4885BCL2L1 955/4885 |
| US-20080113944-A1 | Novel Indole Derivatives | GPR119, FABP4, MC4R | CALM1 1724/4885BCL2 2141/4885BCL2L1 2602/4885 |
| US-20100113536-A1 | HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | GPR119, RPS12, ATP12A | CALM1 3698/4885BCL2 2249/4885BCL2L1 2774/4885 |
| US-20110003752-A1 | New Blood Coagulation Factor Inhibitors | F7, F12, F5 | CALM1 4476/4885BCL2 3206/4885BCL2L1 3061/4885 |
| US-20090118501-A1 | Dicycloalkyl Urea Glucokinase Activators | GCK, GCKR, UCK2 | CALM1 4132/4885BCL2 2011/4885BCL2L1 1532/4885 |
| US-20100197667-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM3, CHRM5 | CALM1 1795/4885BCL2 2193/4885BCL2L1 2178/4885 |
| US-20080319028-A1 | Dicycloalkylcarbamoyl Ureas As Glucokinase Activators | GCK, HK1, GCKR | CALM1 3107/4885BCL2 2830/4885BCL2L1 2885/4885 |
| US-20070004799-A1 | Novel compounds for the treatment of obesity | GPR119, NR4A3, NR4A1 | CALM1 4423/4885BCL2 3324/4885BCL2L1 1864/4885 |
| US-20070027140-A1 | N-heteroaryl indole carboxamides and analogues thereof, for use as glcokinase activators in the treatment of diabetes | GALK1, GCKR, GCK | CALM1 668/4885BCL2 1601/4885BCL2L1 1852/4885 |
| US-20030186944-A1 | Such as 4-(2-(3-dimethylaminobenzoylamino)phenoxy)phthalic acid for treatment/prevention of diabetes; for inhibiting liver glycogen phosphorylase; dietetics | PYGL, GYS2, PYGM | CALM1 1457/4885BCL2 3732/4885BCL2L1 4123/4885 |
| US-20090018161-A1 | METHOD FOR PROMOTING GASTROINTESTINAL FUNCTION AND METHOD FOR SCREENING FOR PROMOTER OF GASTROINTESTINAL FUNCTION | GIPR, GRPR, CCKBR | CALM1 1781/4885BCL2 3539/4885BCL2L1 3511/4885 |
| US-20090062396-A1 | Novel Haloalkoxy-Substituted Salicylic Anilides | FABP4, HDHD5, HSPD1 | CALM1 1846/4885BCL2 2845/4885BCL2L1 2942/4885 |
| US-20140045836-A1 | [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE DERIVATIVES AS HSP90 MODULATORS | HSP90AB1, HSP90AA1, HSP90AB2P | CALM1 873/4885BCL2 887/4885BCL2L1 710/4885 |
| US-20110060019-A1 | HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS | GCK, HK1, HK2 | CALM1 3349/4885BCL2 2791/4885BCL2L1 3248/4885 |
| US-20030045479-A1 | Novel N-formyl hydroxylamine compounds, compositions and methods of use | PDF, HNMT, AADAC | CALM1 4720/4885BCL2 4696/4885BCL2L1 4755/4885 |
| US-20150126477-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, GPR18 | CALM1 432/4885BCL2 363/4885BCL2L1 649/4885 |
| US-20110301158-A1 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | GCK, GCKR, PDK2 | CALM1 2445/4885BCL2 1017/4885BCL2L1 1414/4885 |
| US-20100041657-A1 | HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | RPS12, GPR119, ATP12A | CALM1 3929/4885BCL2 2412/4885BCL2L1 2905/4885 |
| US-20090216013-A1 | e.g.1,1-Dicyclohexyl-3-[5-(pyridin-2-ylsulfanyl)-thiazol-2-yl]-urea; useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial, in particular, type 2 diabetes | GCK, GCKR, HK1 | CALM1 3209/4885BCL2 2495/4885BCL2L1 2510/4885 |
| US-20110281851-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM3, CHRM5 | CALM1 1795/4885BCL2 2193/4885BCL2L1 2178/4885 |
| US-20090325941-A1 | NOVEL 2-(2-HYDROXYPHENYL) BENZOTHIADIAZINES USEFUL FOR TREATING OBESITY AND DIABETES | TXNRD2, GPR119, SLC5A2 | CALM1 3183/4885BCL2 621/4885BCL2L1 1086/4885 |
| US-20090105482-A1 | Urea Glucokinase Activators | GCK, GCKR, HK2 | CALM1 3037/4885BCL2 2460/4885BCL2L1 3716/4885 |
| US-20050113580-A1 | Amide compounds and methods of using the same | NR1H2, NR1H3, PPARA | CALM1 4271/4885BCL2 3836/4885BCL2L1 3905/4885 |
| US-20120122850-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM3, CHRM5 | CALM1 1795/4885BCL2 2193/4885BCL2L1 2178/4885 |
| US-20080119455-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | CALM1 2445/4885BCL2 1017/4885BCL2L1 1414/4885 |
| US-20090005434-A1 | Novel Salicylic Anilides | FABP4, ADIPOR1, ADIPOR2 | CALM1 1657/4885BCL2 3821/4885BCL2L1 3703/4885 |
| US-20060183783-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, PDK3, PDK4 | CALM1 2610/4885BCL2 1605/4885BCL2L1 1717/4885 |
| US-20100249161-A1 | 2- ( 2 -HYDROXYPHENYL) -QUINAZOLIN-4-ONES USEFUL FOR TREATING OBESITY AND DIABETES | GPR119, PGC, FABP4 | CALM1 3858/4885BCL2 1313/4885BCL2L1 2351/4885 |
| US-20080280869-A1 | Pyrazole or Triazole Compounds and Their Use for the Manufacture of a Medicament for Treating Somatic Mutation-Related Diseases | UPF1, RNMT, VHL | CALM1 2638/4885BCL2 3571/4885BCL2L1 3823/4885 |
| US-20150274674-A1 | PYRAZOLE OR TRIAZOLE COMPOUNDS AND THEIR USE FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING SOMATIC MUTATION-RELATED DISEASES | UPF1, RNMT, VHL | CALM1 2638/4885BCL2 3571/4885BCL2L1 3823/4885 |
| US-20120184546-A1 | [1,2,4]TRIAZOLO [1,5-C]PYRIMIDINE DERIVATIVES AS HSP90 MODULATORS | HSP90AB1, HSP90AA1, HSP90AB2P | CALM1 739/4885BCL2 920/4885BCL2L1 658/4885 |
| US-20070004794-A1 | Novel salicylic anilides | FABP4, ADIPOR1, ADIPOR2 | CALM1 1657/4885BCL2 3821/4885BCL2L1 3703/4885 |
| US-20110082144-A1 | N-HETEROARYL INDOLE CARBOXAMIDES AND ANALOGUES THEREOF, FOR USE AS GLUCOKINASE ACTIVATORS IN THE TREATMENT OF DIABETES | GCKR, GCK, GALK1 | CALM1 1934/4885BCL2 1965/4885BCL2L1 2460/4885 |
| US-20110077234-A1 | Urea Glucokinase Activators | GCK, GCKR, HK2 | CALM1 3037/4885BCL2 2460/4885BCL2L1 3716/4885 |
| US-20110130402-A1 | HETEROAROMATIC GLUCOKINASE ACTIVATORS | GCK, GCKR, PDXK | CALM1 4030/4885BCL2 1688/4885BCL2L1 2367/4885 |
| US-20040138301-A1 | Chemical uncouplers for the treatment of obesity | PC, CPT2, IDH2 | CALM1 1863/4885BCL2 377/4885BCL2L1 1916/4885 |
| US-20100204288-A1 | {2-[3-Cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid; useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial; antidiabetic agents | GCK, GCKR, HK1 | CALM1 2155/4885BCL2 2192/4885BCL2L1 2847/4885 |
| US-20070054897-A1 | 1,1-Dicyclohexyl-3-thiazol-2-yl-urea, 3-(5-Chloro-thiazol-2-yl)-1,1-dicyclohexyl-urea, for example; useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial, in particular, type 2 diabetes | GCK, GCKR, HK1 | CALM1 2442/4885BCL2 2232/4885BCL2L1 1767/4885 |
| US-20100075932-A1 | NOVEL SALICYLIC ANILIDES | FABP4, ADIPOR1, ADIPOR2 | CALM1 1657/4885BCL2 3821/4885BCL2L1 3703/4885 |
| US-20110229453-A1 | BLOOD COAGULATION FACTOR INHIBITORS | F5, TFPI, F7 | CALM1 3973/4885BCL2 2622/4885BCL2L1 1869/4885 |
| US-20080234381-A1 | Novel Trifluoromethoxy-Substituted Aryl Anilides | GPR119, FABP4, TFAM | CALM1 3504/4885BCL2 1500/4885BCL2L1 2460/4885 |
| US-20080255240-A1 | Sulfonamide Derivatives | FABP4, SQOR, CS | CALM1 2634/4885BCL2 1969/4885BCL2L1 3238/4885 |
| US-20060281740-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM3, CHRM5 | CALM1 1795/4885BCL2 2193/4885BCL2L1 2178/4885 |
| US-20100063122-A1 | NOVEL 2-(2-HYDROXYPHENYL)BENZIMlDAZOLES USEFUL FOR TREATING OBESITY AND DIABETES | GPR119, HAGH, ALDH2 | CALM1 4185/4885BCL2 831/4885BCL2L1 703/4885 |
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | CALM1 2445/4885BCL2 1017/4885BCL2L1 1414/4885 |
| US-20050176755-A1 | Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists | ITGA4, ITGB4, ITGB7 | CALM1 3321/4885BCL2 3143/4885BCL2L1 4046/4885 |
| US-20080119454-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | CALM1 2445/4885BCL2 1017/4885BCL2L1 1414/4885 |
| US-20030171411-A1 | Amide derivatives as therapeutic agents | GK, GCKR, GCK | CALM1 3117/4885BCL2 4029/4885BCL2L1 3073/4885 |
| US-20060167247-A1 | Urea inhibitors of MAP kinases | MAPK1, MAP3K1, MAP3K20 | CALM1 1468/4885BCL2 2318/4885BCL2L1 2270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.